Harvey J. Alter, MD, Chief, Immunology Section, Department of Transfusion Medicine, Warren G. Magnuson Clinical Center, National Institutes of Health, Bethesda. MD.
Increased detection of hepatitis C virus (HCV)-infected blood donors by a multiple-antigen HCV enzyme immunoassay
Article first published online: 28 FEB 2003
Volume 32, Issue 9, pages 805–813, November-December 1992
How to Cite
KLEINMAN, S., ALTER, H., BUSCH, M., HOLLAND, P., TEGTMEIER, G., NELLES, M., LEE, S., PAGE, E., WILBER, J. and POLITO, A. (1992), Increased detection of hepatitis C virus (HCV)-infected blood donors by a multiple-antigen HCV enzyme immunoassay. Transfusion, 32: 805–813. doi: 10.1046/j.1537-2995.1992.32993110750.x
- Issue published online: 28 FEB 2003
- Article first published online: 28 FEB 2003
- Received for publication May 15, 1992; revision received July 10, 1992, and accepted July 29, 1992.
A new, multiple-antigen enzyme immunoassay (EIA-2) for hepatitis C virus (HCV) antibodies was evaluated in parallel with the previously available c100-3 HCV EIA (EIA-1) in 14,068 volunteer blood donors as well as in 25 cases of transfusion-associated hepatitis C for which recipient and donor samples were available. When compared to EIA-1, the EIA-2 was more sensitive in detecting HCV-infected blood donors. The EIA-2 detected an additional 1 in 1000 EIA-1-negative, surrogate marker- negative donors who were infected with HCV as demonstrated by polymerase chain reaction (PCR). The specificity of the EIA-2 was comparable to that of the EIA-1, but the two tests appear to detect different populations of false-positive donors. Recombinant immunoblot assay-indeterminate donors were detected five times more frequently by the EIA-2; PCR demonstrated that 21 percent of these donors were infected with HCV. The greater sensitivity of EIA-2 was also found in 25 transfusion recipients with non-A, non-B hepatitis; however, in 16 percent of these cases of posttransfusion HCV infection, the EIA-2 failed to detect an HCV-seropositive donor. These data indicate that EIA-2 testing will significantly reduce, but probably not eliminate, the risk of transfusion-associated HCV infection; we estimate this residual per-unit risk to be 1 in 2000 to 1 in 6000 units transfused. On a national level, it is projected that the replacement of the anti- HCV EIA-1 with the EIA-2 will initially prevent up to 40 additional cases of transfusion-associated hepatitis C per day.